Author

Ji Zhou

Institution: AbbVie (United States)

Observed institution: AbbVie (United States)

OpenAlex ID: A5073516640

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn’s Disease

2023 · Edward V. Loftus, Jenny Griffith, et al. · Advances in Therapy · 16

Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease

2023 · Yinuo Pang, Ronilda D'Cunha, et al. · Clinical Therapeutics · 14

S38 On-Body Injector Administration of Risankizumab for Treatment of Moderate-to-Severe Crohn’s Disease: Data From the Fortify Open-Label Longitudinal Real-Life Handling Substudy

2022 · Edward Loftus, Jenny Griffith, et al. · The American Journal of Gastroenterology · 2

Human factors testing of the levodopa-carbidopa intestinal gel delivery system in advanced Parkinson’s disease patients and healthcare providers (P4.009)

2017 · Ramon L. Rodriguez, Hubert H. Fernandez, et al. · Neurology

Usability Testing of Medication Packaging in a Pharmacy Environment

2014 · Kevin Cluff, Mary Mathieu, et al. · Proceedings of the Human Factors and Ergonomics Society Annual Meeting

Works count: 5

Citation count: 32

H-index: 2

I10-index: 2